IXOPAY and Aperia Compliance Merge to Extend Advanced Payment Data Security to Merchant Acquirers and Merchants of All Sizes, Worldwide
Merger combines IXOPAY's enterprise-grade capabilities in payment orchestration and tokenization with Aperia Compliance's PCI DSS Level 3 and 4 solutions.
TULSA, OKLAHOMA / ACCESSWIRE / December 4, 2024 / IXOPAY, a leading payments technology provider handling more than $35 billion in payment volume through its enterprise-grade payment orchestration platform, announced today that it has merged with Aperia Compliance, a subsidiary of Aperia Solutions and a leading firm in Payment Card Industry Data Security Standard (PCI DSS) data validation and risk management. Serving more than 100 merchant acquirers, Aperia Compliance will operate as "Aperia Compliance, an IXOPAY company."
IXOPAY offers enterprise-grade PCI DSS Level 1 and 2 solutions powered by advanced tokenization. Paired with Aperia Compliance's robust PCI DSS Level 3 and 4 solutions-including PCI Apply 4.0 and the new 6.4.3 product-the combined offering aims to deliver a scalable, end-to-end solution enabling merchants, independent sales organizations (ISOs), and payment processors to comply with global data security standards, streamline operations, and drive revenue growth.
"Today's merger with Aperia Compliance enables IXOPAY to extend its capabilities and seeks to provide merchant acquirers of all sizes with powerful tools to navigate updated PCI DSS Version 4.0 requirements and secure their payment systems," said Brady Harris, CEO of IXOPAY. "By combining Aperia Compliance's PCI DSS Level 3 and 4 solutions with our enterprise-grade payments orchestration, we're expanding our platform with the goal of further simplifying compliance, enhancing security, and supporting businesses as they adapt to the evolving payments landscape."
Customers of both companies will now have access to the entire product suite. IXOPAY customers will have access to Aperia Compliance's PCI DSS Level 3 and 4 validation and risk management solutions, which include self-assessment questionnaire assistance, vulnerability scanning, multilingual support, integrated security solutions, data breach protection, merchant education, and reporting and analytics. Aperia Compliance customers-ISOs, processors, banks, and payfacs-gain access to IXOPAY's PCI DSS Level 1 and 2 tokenization and payment orchestration capabilities, along with fraud prevention, automated account updater, 3-D Secure authentication, point-to-point encryption, network token security, and detailed compliance reporting with universal tokens.
"The strategic merger of Aperia Compliance and IXOPAY creates a broader set of tools that enable businesses to compete in the fast-paced payments space," said Kevin Mokarow, Chairman and CEO of Aperia Solutions and senior advisor to the IXOPAY board of directors. "By combining strengths, we're extending IXOPAY's capabilities to small and medium-sized businesses worldwide, aiming to help merchants, ISOs, and processors reduce errors, prevent fraud, and streamline operations for sustainable growth."
The merger with Aperia Compliance is the latest transaction announced by IXOPAY, a portfolio company of K1 Investment Management, following IXOPAY's recent merger with TokenEx and a slate of new executive appointments, including CEO Brady Harris.
"This is another step on the way to creating a payments industry leader," said Tarun Jain, Principal at K1 Investment Management. "Earlier this year, the integration of TokenEx's advanced tokenization technology positioned IXOPAY as a continued innovator in the world of payment data security. With the addition of Aperia Compliance's PCI products, IXOPAY continues to strengthen its platform and help redefine payment operations for businesses worldwide."
Aperia Compliance's management team is continuing with the business under IXOPAY. Aperia Solutions is not a part of the merger and will continue to operate under the Aperia brand.
Media Contact
Mills Forni, Verdis
About IXOPAY
IXOPAY is a leading provider of enterprise-grade payment orchestration, providing a fully integrated platform and flexible payment optimization modules to businesses around the world. With a single API and scalable payments architecture, IXOPAY empowers businesses to streamline, secure, and increase the resilience of their payment systems. Learn more at www.ixopay.com.
About Aperia Compliance
Aperia Compliance, an IXOPAY company, is a leader in Payment Card Industry (PCI) validation and risk management, providing PCI Level 3 and 4 compliance for ISOs, payment processors, and small and medium-sized businesses. Learn more at www.aperia.com/proPCI - Aperiaducts/pci
Contact Information
Mills Forni
Verdis
mills@verdis.xyz
Related Images
|
Source: IXOPAY
View the original press release on accesswire.com
IXOPAY
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom